olfactory receptor family 3 subfamily A member 3Genealiases: OR17-137 · OR17-16 · OR17-201 · OR3A6 · OR3A7 · OR3A8P
Q-omics provides the consensus-scored OR3A3 profile across patient tissues and cancer cell-line models. OR3A3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR3A3 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, OR3A3 RNA expression shows 6,679 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, UCEC, and STAD as cancer lineages where OR3A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR3A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR3A3 survival associations across molecular data types. OR3A3 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR3A3 RNA expression–survival associations across cancer types. High OR3A3 expression shows unfavorable associations in KIRC, KICH, OV, UCEC and KIRP, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for OR3A3 RNA expression.
This table summarizes OR3A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for OR3A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR3A3 shows lower tumor expression in UCEC and KIRC and higher tumor expression in LUAD and HNSC. The UCEC box plot shows higher OR3A3 RNA expression in normal versus tumor tissue (log2 FC = −0.074, t-test p = .015).
This table shows molecular features associated with OR3A3 in patient tissues and cancer cell lines. In patient samples, OR3A3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR3A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LUNG_NSCLC_LUAD.
